Starling Oncology, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Starling Oncology, Inc. (STLN) had Deferred Tax Assets, Operating Loss Carryforwards of $65.74 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $65.74M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $53.42M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $40.36M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $26.36M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $65.74M 10-K · filed 2026-03-12 |
| 2024-12-31 | $53.42M 10-K · filed 2026-03-12 |
| 2023-12-31 | $40.36M 10-K · filed 2025-03-26 |
| 2022-12-31 | $26.36M 10-K · filed 2024-03-28 |
| 2021-12-31 | $12.69M 10-K · filed 2023-03-16 |
| 2020-12-31 | $2.53M 10-K · filed 2022-03-11 |
| 2019-12-31 | $168.00 10-K/A · filed 2021-12-14 |